Processa Pharmaceuticals Files 8-K
Ticker: PCSA · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Aug 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, sec, corporate-event
TL;DR
PRSA filed an 8-K, check for updates.
AI Summary
Processa Pharmaceuticals, Inc. filed an 8-K on August 28, 2024, reporting other events and financial statements. The company, formerly known as Heatwurx, Inc., is incorporated in Delaware and headquartered in Hanover, Maryland.
Why It Matters
This filing indicates Processa Pharmaceuticals is making official disclosures to the SEC, which could relate to significant corporate events or financial updates.
Risk Assessment
Risk Level: low — This is a routine SEC filing (8-K) that typically reports significant events but doesn't inherently carry immediate financial risk on its own.
Key Numbers
- 001-39531 — SEC File Number (Identifies the company's filing with the SEC)
- 45-1539785 — IRS Number (Company's Employer Identification Number)
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- Heatwurx, Inc. (company) — Former company name
- August 28, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Hanover, Maryland (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond stating that this item is being reported.
What is the significance of filing an 8-K on August 28, 2024?
An 8-K filing is required to report significant events that shareholders should be aware of, such as material events, acquisitions, or changes in management.
What was Processa Pharmaceuticals, Inc. formerly known as?
Processa Pharmaceuticals, Inc. was formerly known as Heatwurx, Inc., with a name change date of October 28, 2011.
Where are Processa Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076.
What is the SIC code for Processa Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Processa Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 612 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-08-28 08:00:21
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 111KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001493152-24-034115.txt ( ) — 345KB
- pcsa-20240828.xsd (EX-101.SCH) — 3KB
- pcsa-20240828_lab.xml (EX-101.LAB) — 33KB
- pcsa-20240828_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01. Other Event
Item 8.01. Other Event. On August 28, 2024, Processa Pharmaceuticals, Inc., (The "Company") issued a press release providing updates on its product pipeline, upcoming milestones and business activities, and reports financial results for the three and six months ended June 30, 2024. Safe Harbor Statement Information provided in this Current Report on Form 8-K may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally relate to the Company's plans, objectives and expectations for compensation matters related to Mr. Skibsted's service as the Company's Chief Financial Officer and Mr. Skibsted's start date. Actual future results may differ materially from those projected as a result of certain risks and uncertainties. For a discussion of such risks and uncertainties, see "Risk Factors" as described in the Company's Annual Report for the year ended December 31, 2023 on Form 10-K filed with the Commission on March 30, 2023, the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the Commission on May 10, 2024, and other reports on file with the Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking Item 9.01. Financial Statements and Exhibits. Exhibit No. Exhibit Description 99.1 Press Release providing product pipeline and financial update. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on August 28, 2